BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1142 related articles for article (PubMed ID: 26838599)

  • 1. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
    Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
    Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Fasting-Induced PPARα Activity Does Not Depend on Essential Fatty Acids.
    Polizzi A; Fouché E; Ducheix S; Lasserre F; Marmugi AP; Mselli-Lakhal L; Loiseau N; Wahli W; Guillou H; Montagner A
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.
    Régnier M; Polizzi A; Smati S; Lukowicz C; Fougerat A; Lippi Y; Fouché E; Lasserre F; Naylies C; Bétoulières C; Barquissau V; Mouisel E; Bertrand-Michel J; Batut A; Saati TA; Canlet C; Tremblay-Franco M; Ellero-Simatos S; Langin D; Postic C; Wahli W; Loiseau N; Guillou H; Montagner A
    Sci Rep; 2020 Apr; 10(1):6489. PubMed ID: 32300166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
    Yan F; Wang Q; Xu C; Cao M; Zhou X; Wang T; Yu C; Jing F; Chen W; Gao L; Zhao J
    PLoS One; 2014; 9(6):e99245. PubMed ID: 24926685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
    Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the role of hepatocyte PPARα activity in response to fasting.
    Régnier M; Polizzi A; Lippi Y; Fouché E; Michel G; Lukowicz C; Smati S; Marrot A; Lasserre F; Naylies C; Batut A; Viars F; Bertrand-Michel J; Postic C; Loiseau N; Wahli W; Guillou H; Montagner A
    Mol Cell Endocrinol; 2018 Aug; 471():75-88. PubMed ID: 28774777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic
    Lee YH; Jang HJ; Kim S; Choi SS; Khim KW; Eom HJ; Hyun J; Shin KJ; Chae YC; Kim H; Park J; Park NH; Woo CY; Hong CH; Koh EH; Nam D; Choi JH
    Elife; 2021 Dec; 10():. PubMed ID: 34964438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
    Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
    Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.
    Tanaka N; Takahashi S; Zhang Y; Krausz KW; Smith PB; Patterson AD; Gonzalez FJ
    Biochim Biophys Acta; 2015 Jul; 1852(7):1242-52. PubMed ID: 25736301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3R3 regulates PPARα expression to stimulate fatty acid β-oxidation and decrease hepatosteatosis.
    Yang X; Fu Y; Hu F; Luo X; Hu J; Wang G
    Exp Mol Med; 2018 Jan; 50(1):e431. PubMed ID: 29350678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
    Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
    Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
    Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
    Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
    Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
    Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
    J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα.
    Ducheix S; Podechard N; Lasserre F; Polizzi A; Pommier A; Murzilli S; Di Lisio C; D'Amore S; Bertrand-Michel J; Montagner A; Pineau T; Loiseau N; Lobaccaro JM; Martin PG; Guillou H
    Biochimie; 2013 Mar; 95(3):556-67. PubMed ID: 23063693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
    Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
    J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.